The content on this site is intended for healthcare professionals only
Dr Davide Maffei speaks to ecancer at EMUC 2019 in Vienna about the discrepancies between the work of his centre, which focusses on using micro-ultrasound diagnosis.
Dr Maffei gives a very thorough account of his study, including the way clinically significant lesions are identified, right through to the results of the study.
He ends by explaining what changes will come to clinical practise because of this, including cost-effectiveness.
Part 1: Why test?
BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer
SABCS 2025: Latest developments in multigene testing in early breast cancer
New classification for identifying HR myeloma based on cytogenetic abnormalities
Predicting tumour mutations from pathology images may help increase personalised medicine utilisation
Choosing Wisely for young women with breast cancer: Radiotherapy
Cancer mutation prediction using artificial intelligence
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Best practice in HRRm testing in patients with metastatic prostate cancer
